BlinkLab Limited

BlinkLab Limited: Transforming Mental Healthcare through Mobile-based AI App


Australia-based BlinkLab leverages computer vision, artificial intelligence and machine learning by developing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD. The app turns the mobile phone into a medical device for an effortless way of conducting remote and rapid tests.

The BlinkLab Test aims to perform neurobehavioural testing free from facial instruments or other fixed location equipment. This AI-based platform is designed to be used at home or in similar environments, independently or with the assistance of a caregiver while following instructions from the mobile device application.

Blinklab test

In collaboration with Princeton University in the US and Erasmus Medical Center in the Netherlands, Blinklab Test is initially developed as a prescription diagnostic aid to healthcare professionals (HCP). BlinkLab will need to complete a pivotal registrational study and subsequently apply for FDA registration and reimbursement for the tests.

Company Highlights

  • Australia-based BlinkLab is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed at Princeton University.
  • The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.
  • Once approved by the regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.
  • BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.

This BlinkLab is part of a paid investor education campaign.*

Click here to connect with BlinkLab to receive an Investor Presentation

The Conversation (0)
Rocketboots Limited

RocketBoots Renews Contract with Major Australian Retailer

Artificial Intelligence software company RocketBoots Limited (ASX:ROC) (RocketBoots or the Company), is pleased to announce that it has extended a foundation partnership with a major Australian retailer (the Customer)1 for the provision of ROC software across its retail locations.

Keep reading...Show less
Customer support visualization.

Investing in Conversational AI: Understanding the Technology and Opportunities

Artificial intelligence in the enterprise landscape is rapidly evolving, paving the way for game-changing innovations that are reshaping the face of customer service. At the forefront of this transformation is conversational AI.

This technology, which encompasses natural language processing, machine learning, and automatic speech recognition, is revolutionizing how businesses interact with customers and streamline operations. For investors seeking to capitalize on emerging trends, investing in conversational AI technology presents a compelling opportunity.

Keep reading...Show less
Woman watches child wearing headphones use tablet.

AI and Mobile Tech Offer Game-changing Shift in Autism Diagnosis

The convergence of artificial intelligence (AI) and mobile technology is ushering in a new era of healthcare diagnostics, particularly in neurodevelopmental conditions such as autism.

This technological synergy is not only transforming patient care through early detection and intervention, but is also creating compelling investment opportunities in the rapidly expanding healthcare AI market.

Investigating this emerging medical technology sector can provide valuable insights for investors who are looking to capitalize on these early-stage innovations.

Keep reading...Show less
A microchip with an American flag on it.

Biden Admin Awards Intel US$7.9 Billion for Semiconductor Sector Growth

The Biden administration has announced a US$7.87 billion funding agreement with Intel (NASDAQ:INTC) under the CHIPS Incentives Program as part of its efforts to bolster the US semiconductor manufacturing industry.

The award represents one of the most substantial semiconductor manufacturing investments facilitated by the CHIPS for America program.

Intel plans to invest over US$90 billion in the United States by the end of the decade, enhancing the US capacity for manufacturing leading-edge semiconductors. These advanced chips are integral to crucial industries such as artificial intelligence and defense systems.

Keep reading...Show less

Latest Press Releases

Related News

×